Carfilzomib
- Generic Name
- Carfilzomib
- Brand Names
- Kyprolis
- Drug Type
- Small Molecule
- Chemical Formula
- C40H57N5O7
- CAS Number
- 868540-17-4
- Unique Ingredient Identifier
- 72X6E3J5AR
- Background
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.
- Indication
Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone. It is also i...
- Associated Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM)
- Associated Therapies
- -
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2012-08-15
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 101
- Registration Number
- NCT01665794
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇨🇦University Health Network - Princess Margaret Cancer Center, Toronto, Ontario, Canada
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma
- Conditions
- Interventions
- First Posted Date
- 2012-08-09
- Last Posted Date
- 2017-10-18
- Lead Sponsor
- Criterium, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT01660750
- Locations
- 🇺🇸
Samuel Oschin Comprehensive Cancer Center at Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸University of Massachusettes Memorial, Worcester, Massachusetts, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma
- Conditions
- Interventions
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2016-06-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3
- Registration Number
- NCT01658904
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2012-04-06
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 55
- Registration Number
- NCT01572480
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2012-04-02
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 929
- Registration Number
- NCT01568866
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇦🇺Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇺🇸Winship Cancer Institute, Atlanta, Georgia, United States
Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2012-03-21
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 74
- Registration Number
- NCT01559935
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2012-03-09
- Last Posted Date
- 2019-01-16
- Lead Sponsor
- Emory University
- Target Recruit Count
- 32
- Registration Number
- NCT01549431
- Locations
- 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸Emory University Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2012-02-23
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 7
- Registration Number
- NCT01537861
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2011-12-21
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 80
- Registration Number
- NCT01496118
- Locations
- 🇺🇸
Florida Cancer Specialists South, Fort Myers, Florida, United States
🇺🇸Tennessee Oncology-Chattanooga, Chattanooga, Tennessee, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia
- Conditions
- Interventions
- First Posted Date
- 2011-11-11
- Last Posted Date
- 2018-11-20
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 31
- Registration Number
- NCT01470196
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.